GOLDSMITH MARK A 4

What Happened

• Mark A. Goldsmith, President and Chief Executive Officer of Revolution Medicines (RVMD), sold 12,871 shares on March 17, 2026 at $99.48 per share for a total of approximately $1,280,412. The filing reports the sale as an open-market or private sale and is reported as a disposition (S).

Key Details

• Transaction date and price: 2026-03-17, 12,871 shares at $99.48 each.
• Gross proceeds: about $1,280,412.
• Shares owned after transaction: the filing does not list a total post-transaction share count; it does note beneficial holdings include 201,150 RSUs (footnote F2).
• Footnotes/ownership notes: transaction was made under a Rule 10b5-1 instruction letter adopted May 31, 2023 to satisfy the reporting person’s tax withholding obligation upon RSU vesting after July 15, 2023 (F1). Some holdings are held in trusts (F3–F5).
• Filing timeliness: reported on Form 4 filed March 19, 2026 for the March 17, 2026 transaction — appears timely.

Context

• The sale was executed under a pre-established 10b5-1 plan to cover tax withholding tied to restricted stock unit vesting, which is a routine reason for insider sales and does not necessarily reflect a change in view on the company.